Lipocine

$1.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-2.45%) Today
+$0.01 (+0.63%) As of 5:00 PM EST after-hours

Why Robinhood?

You can buy or sell Lipocine and other stocks, options, and ETFs commission-free!

About LPCN

Lipocine Inc. Common Stock, also called Lipocine, is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT. The listed name for LPCN is Lipocine Inc. Common Stock.

CEO
Mahesh V. Patel
Employees
12
Headquarters
Salt Lake City, Utah
Founded
2011
Market Cap
104.44M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.40M
High Today
$1.65
Low Today
$1.56
Open Price
$1.65
Volume
1.54M
52 Week High
$2.39
52 Week Low
$0.301

Collections

LPCN Earnings

-$0.16
-$0.11
-$0.05
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, Pre-Market

You May Also Like